620 related articles for article (PubMed ID: 31684965)
1. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
[TBL] [Abstract][Full Text] [Related]
2. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
4. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
6. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
7. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
8. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
Tariq SM; Thomas EC
Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
[TBL] [Abstract][Full Text] [Related]
10. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
11. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
13. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
14. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
15. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
16. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
17. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW; Kim HJ; Jang EJ; Lee CH
Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]